52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Novavax Appoints Leadership Team To Advance Nanoflu Through Regulatory Licensure
Endo Announces Fill-Finish Manufacturing And Services Agreement For Novavax Covid-19 Vaccine Candidate
Novavax Initiates Phase 3 Efficacy Trial Of COVID-19 Vaccine In The United Kingdom
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
Biotechnology & Drugs
21 Firstfield Rd
James Francis Young
Independent Chairman of the Board
Stanley C. Erck
President, Chief Executive Officer, Director
John J. Trizzino
Executive Vice President, Chief Business Officer, Chief Financial Officer and Treasurer
Gregory M. Glenn
President, Research and Development
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/COVID-19 vaccine for use after the pandemic.
Serum Institute of India will make up to 200 million COVID-19 vaccine doses for poorer countries, including India, next year, as the Bill & Melinda Gates Foundation and GAVI vaccines alliance have doubled their funding, the company said on Tuesday.
More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human trials, according to the World Health Organization (WHO). The following list tracks the latest developments from major drugmakers and research institutes...
Generic drugmaker Endo said on Friday it was manufacturing Novavax Inc's experimental COVID-19 vaccine, sending its shares up 10% before the trading bell.
Novavax Inc has signed an agreement with Endo International for manufacturing its experimental COVID-19 vaccine, the generic drugmaker said on Friday.
Novavax Inc on Thursday started a late-stage trial of its experimental COVID-19 vaccine in the United Kingdom in partnership with the government's Vaccines Taskforce, sending the company's shares up 6% after the bell.
Novavax Inc on Thursday started a late-stage trial of its experimental COVID-19 vaccine in partnership with the UK government's Vaccines Taskforce.
U.S. drug developer Novavax Inc said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India, sending its shares up about 7%.
Novavax Inc is doubling its COVID-19 vaccine manufacturing capacity to two billion doses under an agreement with Serum Institute of India, the U.S. company said on Tuesday.
Canada reached an agreement in principle on Monday with both Novavax Inc and Johnson & Johnson for millions of doses of their experimental coronavirus vaccines, Prime Minister Justin Trudeau said.
Novavax Inc said on Monday it had reached an agreement in principle with Canada to supply up to 76 million doses of its experimental coronavirus vaccine.
U.S. drug developer Novavax Inc said on Monday it started a mid-stage study of its experimental COVID-19 vaccine in South Africa, as the country experiences a surge in coronavirus cases.
* Over 300 million doses secured to up chances of one that works
U.S. drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373.
The UK government has sealed two more deals to secure COVID-19 vaccines, buying shots in development from U.S. drugmakers Johnson & Johnson and Novavax Inc, the chair of the UK Vaccine Taskforce Katie Bingham told Sky News on Friday.
Novavax Inc said on Thursday South Korea's SK bioscience would manufacture a component of the U.S. drug developer's experimental coronavirus vaccine in a bid to boost its supply.
Novavax Inc said on Thursday South Korea's SK bioscience will manufacture a component of the U.S. drug developer's experimental coronavirus vaccine.
Novavax Inc's manufacturing capacity is sufficient to meet the U.S. demand for COVID-19 vaccines in 2021, which it believes could be as high as 500 million to 600 million doses, company executives said on Monday.
Takeda Pharmaceutical will manufacture and sell up to 250 million doses of Novavax Inc's COVID-19 vaccine candidate in Japan every year, the two companies said on Friday.
Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.